Navigation Links
Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Date:9/6/2012

SEATTLE, Sept. 6, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders. OMS824 selectively inhibits PDE10, which is an enzyme expressed in areas of the brain linked to diseases that affect cognition, including schizophrenia and Huntington's disease. 

The first clinical trial evaluating OMS824 is expected to commence following the FDA's review of the IND. This Phase 1 dose-ranging study will evaluate the drug's safety, tolerability and pharmacokinetics in healthy subjects and, assuming timely clearance by the FDA, Omeros plans to begin enrollment in the fourth quarter of 2012 with data expected before year end.

"The deep and diverse pipeline behind our PharmacoSurgery™ platform has now begun to yield clinical programs," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.  "OMS824 represents the first new chemical entity developed wholly within Omeros that has progressed from discovery through preclinical development and is now poised to enter the clinic, underscoring our in-house capabilities to generate promising novel compounds and build them into clinical assets. Together with our Phase 1 trial results for OMS824, we also expect to announce data later this year from our two ongoing Phase 3 clinical development programs, OMS302 for ophthalmology and OMS103HP for arthroscopy."

About Omeros' PDE10 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition, including schizophrenia and Huntington's disease. Cognitive dysfunction occurs early in these diseases and is respon
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:7/10/2014)... July 10, 2014   LabStyle Innovations Corp ... today announced the appointment of Professor Richard ... its Board of Directors. Prof. Stone ... experience to LabStyle as an entrepreneur, venture capitalist ... corporate governance expert. He currently serves on the ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 ... nephrologists report awareness of the U.S. Food and Drug ... Pharma,s new phosphate binder Velphoro, which was approved by ... hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
(Date:7/11/2014)... York, New York (PRWEB) July 11, 2014 ... http://www.transvaginalmeshlawsuithelp.com/ ) , filed against Johnson & Johnson’s ... courts, Bernstein Liebhard LLP notes that the Texas ... investigating the company’s marketing of surgical mesh products ... urinary incontinence. According to a report from kens5.com, ...
(Date:7/11/2014)... Butler Mobility has recently updated the paint color choices ... Previously the two standard colors were beige and brown. ... as standard colors at no additional charge! These colors ... enhance the beauty of the stairway. Homeowners will find ... individual décor. , The new selection of standard colors is: ...
(Date:7/11/2014)... News) -- Reducing the number of deer in an ... and other tick-borne infections among people, new research indicates. ... manipulated to reduce human interactions with deer, infected nymphal ... researchers wrote. White-tailed deer are the primary host ... people. The study included nearly all the permanent ...
(Date:7/11/2014)... (HealthDay News) -- People with the lowest incomes may have ... disease (PAD), a new study suggests. People with PAD ... limbs, most often the legs. The condition causes leg pain ... throughout the body. People with PAD have a higher risk ... nearly 6,800 people with PAD who took part in the ...
(Date:7/11/2014)... Dennis Thompson HealthDay Reporter ... Mississippi girl born with HIV who was thought to be ... new tests showing detectable levels of the AIDS-causing virus in ... girl, now nearly 4 years old, had remained virus-free even ... months old. Doctors had hoped her remission would open the ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3
... SAN FRANCISCO, Sept. 15 The Gladstone ... Quantitative Biomedical Research (QB3) at the University of California, ... (CDD) are pleased to announce the prestigious speakers and ... Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian ...
... (Sept. 15, 2009) A research project looking for ... of improving the bone health of cancer patients undergoing radiation ... microgravity environment of space causes bone loss in astronauts, but ... radiation on bones. Dr. Ted Bateman leads a project funded ...
... , , , ... the innovative healthcare company supporting the nation,s foremost cancer treatment and ... 2009 InformationWeek 500, an annual listing of the nation,s most innovative ... establishment of an enterprise-wide CRM platform. , , ...
... could improve long-term health, researchers say , TUESDAY, Sept. ... a greater risk of becoming obese in adulthood, new ... online Sept. 11 in the journal BMC Medicine ... Psychiatry Center at the Institute of Psychiatry at King,s ...
... , BURBANK, Calif., Sept. 15 ... Los Angeles and the Childrens Hospital Los Angeles Medical Group has ... treatment for a group that nationwide falls in a gap between ... The Adolescent & Young Adult Cancer Program ...
... Industries have ... million since ... and campaign ... and HMO political contributions and lobbying expenses found the industries spent $126,430,438 over the first half of 2009 and ...
Cached Medicine News:Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 2Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 3Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 4Health News:Space-related radiation research could help reduce fractures in cancer survivors 2Health News:Space-related radiation research could help reduce fractures in cancer survivors 3Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 2Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 3Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 4Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 5Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 6Health News:Anxious Kids at Risk for Obesity in Adulthood 2Health News:Young Adults with Cancer Focus of Program Developed by Providence Saint Joseph Medical Center and Childrens Hospital Los Angeles 2Health News:Young Adults with Cancer Focus of Program Developed by Providence Saint Joseph Medical Center and Childrens Hospital Los Angeles 3Health News:Insurance and HMO Industries Spend Nearly $700,000 Per Day to Kill Health Care Reform Measures 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: